Pages that link to "Q67985671"
Jump to navigation
Jump to search
The following pages link to Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations (Q67985671):
Displaying 50 items.
- Interventions for infantile haemangiomas (strawberry birthmarks) of the skin (Q24234433) (← links)
- Interventions for infantile haemangiomas (Q24245891) (← links)
- Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1 (Q28768582) (← links)
- Risks and benefits of interferon-alpha in the treatment of hepatitis (Q33496785) (← links)
- Immunomodulation in horses (Q33884213) (← links)
- High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. (Q34214186) (← links)
- Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. (Q34377809) (← links)
- Cutaneous T-cell lymphoma. New immunomodulators (Q34436506) (← links)
- Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. (Q34517293) (← links)
- Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. (Q34579182) (← links)
- Cytokine therapeutics: lessons from interferon alpha (Q35033232) (← links)
- Prevention of human hepatocellular carcinoma with natural lymphoblastoid alpha interferon (Q35048281) (← links)
- Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals (Q35212578) (← links)
- Treatment of acute and chronic hepatitis C. (Q35960898) (← links)
- Treatment of HCV: approach to difficult cases (Q35960907) (← links)
- The Use of Interferon-α in Virus Infections (Q36711548) (← links)
- Deterioration of mixed cryoglobulinemia during treatment with interferon-alpha-2a (Q38913560) (← links)
- Effect of dosing schedule on pharmacokinetics of alpha interferon and anti-alpha interferon neutralizing antibody in mice. (Q39475942) (← links)
- Clinical toxicity of the interferons. (Q40390091) (← links)
- Interferons for viral hepatitis (Q40399739) (← links)
- Recent advances in the treatment of human immunodeficiency virus infections with interferons and other biological response modifiers (Q40400548) (← links)
- Interferon-alpha in malignant and viral diseases. A review (Q40485713) (← links)
- Biological basis for the clinical use of interferon (Q40487772) (← links)
- Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. (Q40862556) (← links)
- Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis (Q40961282) (← links)
- Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy (Q41433339) (← links)
- The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors (Q41567251) (← links)
- 14 Treatment of chronic myeloid leukaemia: some topical questions (Q41648126) (← links)
- Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa (Q42987319) (← links)
- Effectiveness of leukocyte interferon-alpha treatment in patients with chronic hepatitis C not responsive to recombinant interferon (Q42990573) (← links)
- Neutralizing antibodies to interferon‐α and circulating interferon in patients with chronic hepatitis C non‐responding to pegylated interferon plus ribavirin re‐treated by pegylated interferon‐α‐2a and ribavirin (ANRS HC16 GAMMATRI substudy*) (Q43000916) (← links)
- Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon (Q43041718) (← links)
- Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia (Q43048085) (← links)
- Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. (Q43048315) (← links)
- Evidence against an autoimmune aetiology for inflammatory bowel diseases (Q43221507) (← links)
- Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha (Q45789815) (← links)
- The treatment of choroidal neovascular membranes by alpha interferon. An efficacy and toxicity study (Q46527056) (← links)
- Neutralising and binding anti-interferon-β-1 b (IFN-b-1 b) antibodies during IFN-β-1 b treatment of multiple sclerosis (Q48686221) (← links)
- Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity (Q52009627) (← links)
- Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α. (Q52564132) (← links)
- Interventions for infantile haemangiomas of the skin. (Q53280418) (← links)
- RETRACTED: Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial (Q56765707) (← links)
- Cochrane Review: Interventions for infantile haemangiomas (strawberry birthmarks) of the skin (Q57341620) (← links)
- A comparison of four types of interferon alpha in the treatment of chronic hepatitis C (Q59388270) (← links)
- De novo design of potent and selective mimics of IL-2 and IL-15 (Q60962219) (← links)
- Absence of circulating interferon in patients with inflammatory bowel disease. Suggestion against an autoimmune etiology (Q67543231) (← links)
- Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment (Q68032505) (← links)
- High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial (Q70910448) (← links)
- Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction (Q71169395) (← links)
- The naming of cats--and alpha-interferons (Q71264419) (← links)